(Q37607063)

21 August 2017

1 reference

title

Treatment of rheumatoid arthritis: state of the art 2009. (English)

1 reference

21 August 2017

1 reference

Ronald van Vollenhoven

series ordinal

1

object named as

Ronald F van Vollenhoven

0 references

language of work or name

English

0 references

publication date

1 October 2009

1 reference

Nature Reviews Rheumatology

21 August 2017

published in

1 reference

21 August 2017

volume

5

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

531-541

1 reference

Treatment of rheumatoid arthritis. New thoughts on the classic pyramid approach

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Inverting the therapeutic pyramid: observations and recommendations on new directions in rheumatoid arthritis therapy based on the author's experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Efficacy of low-dose methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis. A thirty-six-week, double-blind trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Comparison of azathioprine, methotrexate, and the combination of the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled clinical trial with radiologic outcome assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Validation of rheumatoid arthritis improvement criteria that include simplified joint counts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

The hierarchy of quality-of-life assessment, the Health Assessment Questionnaire (HAQ), and issues mandating development of a toxicity index

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

How to dose infliximab in rheumatoid arthritis: new data on a serious issue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Promising bone-related therapeutic targets for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

IL-17 as a future therapeutic target for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Regulatory T cells as therapeutic targets in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

CD19: a promising B cell target for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Dendritic cells as targets for therapy in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Rejuvenating the immune system in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2009.182

Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

12 December 2020

Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study

1 reference

12 December 2020

Low dose prednisone therapy in rheumatoid arthritis: a double blind study

1 reference

12 December 2020

The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales

1 reference

12 December 2020

The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis

1 reference

12 December 2020

How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies.

1 reference

12 December 2020

Toxicity of low dose methotrexate in rheumatoid arthritis.

1 reference

12 December 2020

Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis

1 reference

12 December 2020

The health assessment questionnaire 1992: status and review

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRRHEUM.2009.182

1 reference

21 August 2017

1 reference